MrBiggy schreef op 14 augustus 2023 11:46:
Daar heeft Gilead al veel eerder over nagedacht:
'So far, company CEO Dan O'Day has moved to tie Gilead's future closer with that of Belgian drugmaker Galapagos, developer of the rheumatoid arthritis drug filgotinib. O'Day acknowledged, however, the company has a "sense of urgency" to build up its research pipeline further, with oncology a likely target.
"We're actively pursuing and evaluating innovative programs and technologies externally to build our presence in oncology," said Merdad Parsey, Gilead's new chief medical officer, on a call with investors Tuesday evening.
Gilead's interest, Parsey noted, is in other cancer treatment approaches as well as cell therapy.'www.biopharmadive.com/news/gilead-yes...
dat was Published Feb. 5, 2020